Jaguar Health (NASDAQ:JAGX) stock is taking a beating on Tuesday after the commercial-stage pharmaceuticals company reported results from a Phase 3 clinical trial. The bad news for investors in JAGX shareholders is this clinical trial failing to meet its primary endpoint. The trial covered 10 different tumor types but crofelemer was only effective in patients with breast and respiratory cancers. "Clinical meaningfulness of these results is based on the information provided by solid tumor patients from a sur ...